News and Announcements
Kazia (ASX: KZA) commences fifth trial of GDC-0084 with leading US cancer centre
- Published August 15, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Highlights
- Kazia Therapeutics has announced that Memorial Sloan Kettering Cancer Center in New York will investigate the potential use of GDC-0084 for cancer that has spread to the brain.
- The new trial will investigate whether GDC-0084 has the potential to enhance the effects of radiotherapy as treatment for patients with solid tumour brain metastases.
- The trial will involve 18-30 patients over a period of two years bringing the total number of ongoing trials with GDC-0084 to five.
Australian biotechnology company Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), has announced that Memorial Sloan Kettering Cancer Center (MSK) in New York will investigate the potential use of Kazia’s investigational new drug, GDC-0084. The drug will be investigated in combination with radiotherapy in phase I clinical trial for cancer that has spread to the brain.
Research shows up to 30% of patients with metastatic cancer will develop secondary tumours in the brain. Despite the best care utilising radiotherapy as treatment, 30-50% of patients will progress within a year.
The new trial will investigate whether GDC-0084 has the potential to enhance the effects of radiotherapy as treatment for patients with solid tumour brain metastases along with leptomeningeal metastases. It is testing the hypothesis that GDC-0084 will assist in radiotherapy resistance. In recent animal models of some brain cancers, activation of the PI3K pathway has contributed to radiotherapy resistance. Implementation of GDC-0084 is used as a PI3K inhibitor that crosses the blood-brain barrier in an attempt to reduce radiotherapy resistance.
About Kazia Therapeutics Limited
Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications.
Company Updates
The Index Approach in Early-Stage Venture Capital: Reconsidered
The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]
The Future Is Now: The Evolution of Dealflow with Wholesale Investor
If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]
Investability of a Startup: A Comprehensive Guide for Angels and High-Net Worth Investors
Venturing into the Startup Scene Let’s dive into the intriguing world of startups. It’s a thrilling ride, isn’t it? Like finding a pearl in an ocean, spotting a promising startup amidst a sea of businesses is no easy task. This guide aims to light the way, focusing on the “The Investability of a Startup: 7 […]
Backed By Leading Investment Groups and Family Offices
